ORCiD
Adam M. Kaye: 0000-0002-7224-3322
Document Type
Article
Publication Title
Health Psychology Research
ISSN
2420-8124
Volume
10
Issue
3
First Page
37517
Last Page
37517
Publication Date
1-1-2022
Abstract
Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
Recommended Citation
Poliwoda, S.,
Noor, N.,
Jenkins, J. S.,
Stark, C. W.,
Steib, M.,
Hasoon, J.,
Varrassi, G.,
Urits, I.,
Viswanath, O.,
Kaye, A. M.,
&
Kaye, A. D.
(2022).
Buprenorphine and its formulations: a comprehensive review..
Health Psychology Research, 10(3), 37517–37517.
https://scholarlycommons.pacific.edu/phs-facarticles/662
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Chemicals and Drugs Commons, Pharmacy and Pharmaceutical Sciences Commons
